127 related articles for article (PubMed ID: 28533634)
1. Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of
Arora G; Mishra R; Kumar P; Yadav M; Ballal S; Bal C; Damle NA
Indian J Nucl Med; 2017; 32(2):89-92. PubMed ID: 28533634
[TBL] [Abstract][Full Text] [Related]
2. Radiation Dose to the Occupational Worker during the Synthesis of
Thakral P; Jyotsna ; Tandon P; Dureja S; Pant V; Sen I
Indian J Nucl Med; 2018; 33(1):1-5. PubMed ID: 29430106
[TBL] [Abstract][Full Text] [Related]
3. Blood clearance and occupational exposure for
Abuqbeitah M; Demir M; Uslu-Beşli L; Yeyin N; Sönmezoğlu K
Radiat Environ Biophys; 2018 Mar; 57(1):55-61. PubMed ID: 29149420
[TBL] [Abstract][Full Text] [Related]
4. Labelling of
Iori M; Capponi PC; Rubagotti S; Esposizione LR; Seemann J; Pitzschler R; Dreger T; Formisano D; Grassi E; Fioroni F; Versari A; Asti M
Contrast Media Mol Imaging; 2017; 2017():8160134. PubMed ID: 29097938
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
Demir M; Abuqbeitah M; Uslu-Beşli L; Yıldırım Ö; Yeyin N; Çavdar İ; Vatankulu B; Gündüz H; Kabasakal L
J Radiol Prot; 2016 Jun; 36(2):269-78. PubMed ID: 27089552
[TBL] [Abstract][Full Text] [Related]
6. An Intrapatient Dosimetry Comparison of
Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
[TBL] [Abstract][Full Text] [Related]
7. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
8. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
9.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
10. Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.
Abbasi IA
World J Nucl Med; 2015; 14(2):95-100. PubMed ID: 26097419
[TBL] [Abstract][Full Text] [Related]
11. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
[TBL] [Abstract][Full Text] [Related]
12. Preparation of Patient Doses of [
Nanabala R; Pillai MRA; Gopal B
Nucl Med Mol Imaging; 2022 Dec; 56(6):313-322. PubMed ID: 36425271
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
14. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
15. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
[TBL] [Abstract][Full Text] [Related]
16. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
[TBL] [Abstract][Full Text] [Related]
17. Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
Mukherjee A; Lohar S; Dash A; Sarma HD; Samuel G; Korde A
J Labelled Comp Radiopharm; 2015 Apr; 58(4):166-72. PubMed ID: 25765604
[TBL] [Abstract][Full Text] [Related]
18. Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.
Ladrière T; Faudemer J; Levigoureux E; Peyronnet D; Desmonts C; Vigne J
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111725
[TBL] [Abstract][Full Text] [Related]
19. Pretherapeutic Comparative Dosimetry of
Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
[TBL] [Abstract][Full Text] [Related]
20. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]